Today’s ETF Alert: Fidelity Limited Term Bond ETF (FLTB) Declines 0.02% for Nov 16

November 16, 2016 - By Louis Casey   ·   0 Comments

Nov 16 is a negative day so far for Fidelity Limited Term Bond ETF (NYSEARCA:FLTB) as the ETF is active during the day after losing 0.02% to hit $50.24 per share. The exchange traded fund has 121.70 million net assets and 0.27% volatility this month.

Over the course of the day 241 shares traded hands, as compared to an average volume of 58,160 over the last 30 days for Fidelity Limited Term Bond ETF (NYSEARCA:FLTB).

The ETF is -3.70% of its 52-Week High and 5.10% of its low, and is currently having ATR of 0.15. This year’s performance is 2.44% while this quarter’s performance is -1.01%.

The ETF’s YTD performance is 3.54%, the 1 year is 2.54% and the 3 year is NaN%.

The fund’s top holdings are: US Treasury Note 0.75% for 7.41% of assets, US Treasury Note 0.875% for 2.87%, Ford Motor Credit Co 3.157% for 1.87%, Bk Amer 2.65% for 1.56%, US Treasury Note 1.125% for 1.41%, US Treasury Note 1.625% for 1.28%, Goldman Sachs Grp 2.625% for 1.23%, Mitsubishi Ufj Finl Grp 2.95% for 1.11%, Anheuser Busch Inbev Fin 2.15% for 1.01%.

More notable recent Fidelity Merrimack Street Trust (NYSEARCA:FLTB) news were published by: which released: “Fidelity fund becomes pace setter in charity” on November 12, 2014, also with their article: “‘It’s Always Sunny’ Star Charlie Day Pushes Students To Take Risks In …” published on May 21, 2014, published: “Winners’ Circle: The Top US-Stock Mutual Funds” on July 06, 2014. More interesting news about Fidelity Merrimack Street Trust (NYSEARCA:FLTB) were released by: and their article: “‘It’s Always Sunny’ star Charlie Day gave one of the funniest commencement …” published on April 15, 2015 as well as‘s news article titled: “Trade-Ideas: Merrimack Pharmaceuticals (MACK) Is Today’s Strong On High …” with publication date: July 29, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Louis Casey

Readers Comments (0)

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News